Hemophilia is a rare hereditary (inherited) disorder in which the blood does not clot properly, leading to extended bleeding.
Hemophilia results from a missing or deficient protein (clotting factor) needed for blood clotting. The two main forms are hemophilia A (factor VIII deficiency) and hemophilia B (factor IX deficiency).
Other Rare Bleeding Disorders are defined by congenital deficiencies of other blood coagulation factors, including Factors II, V, VII, X, and XI.
Alnylam Pharmaceuticals, Inc. (ALNY) reported initial evidence for potential correction of the Hemophilia Phenotype from its ongoing Phase 1 study of ALN-AT3, a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia and rare bleeding disorders.
According to these new data, subcutaneous administration of ALN-AT3 in hemophilia subjects was generally well tolerated, achieved antithrombin knockdown of up to 70%, increased thrombin generation by up to 334%, and markedly improved whole blood clotting.
Thrombin is the principal enzyme of hemostasis, the overall process by which bleeding because of blood vessel damage is halted. It catalyzes the conversion of fibrinogen to fibrin and activates procoagulant factors V, VIII, XI, and XIII.
The ALN-AT3 Phase 1 study continues to enroll hemophilia subjects in additional dose cohorts, including the potential to explore a once-monthly subcutaneous dose regimen following a protocol amendment. ALNY plans to present additional data from the Phase 1 study in mid-2015, and then additional results in late 2015. In addition, ALNY expects to initiate a Phase 2 study of ALN-AT3 in late 2015.
ALNY is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. RNAi is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development.
More about Alnylam Pharmaceuticals, Inc. (ALNY) at www.alnylam.com
**
Xenoport, Inc. (XNPT) reported that sales of HORIZANT(R) (gabapentin enacarbil) Extended-Release Tablets are growing, and the company believes that it has just begun to unlock the potential value of this product for its stockholders.
According to XNPT, the number of nation-wide prescribed tablets for the 13 weeks ending December 19, 2014 was 1,256,082, an increase of 18% compared to the previous 13 weeks and a 95% increase year over year.
The rolling four-week average of prescribed tablets for the week ending December 19, 2014 was 100,742. The current wholesale acquisition cost (WAC) price is $7.69 per tablet
During the third quarter of 2014, XNPT increased its field sales force of NeuroHealth Sales Specialists and believes that prescriptions will continue to experience strong growth in 2015.
XNPT also said that in the fourth quarter of 2014, representatives from the company and the National Institutes for Alcohol Abuse and Alcoholism (NIAAA) conducted a pre-investigational new drug (IND) meeting with the FDA.
Based on the meeting, XNPT believes that the FDA has accepted the NIAAA’s design of the proposed pivotal clinical trial of HORIZANT as a potential treatment for Alcohol Use Disorder.
HORIZANT, discovered and developed by XNPT, was approved in the United States in July 2011 for the treatment of moderate-to-severe primary restless legs syndrome in adults and in June 2012 for the management of postherpetic neuralgia in adults.
XNPT is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders.
More about Xenoport, Inc. (XNPT) at www.XenoPort.com.
**
Crown Equity Holdings Inc. (CRWE) is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included the city of Glendale, California ( www.glendale.crwe-pr.com ) into the CRWE Network.
Glendale is located in southern California. It is the third largest city in Los Angeles County, after LA and Long Beach.
The City of Glendale had an estimated population in 2013 (U.S. Census Bureau) of 196,021, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S., associated with 3456 ZIP Codes, and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance ( www.finance.crwe-pr.com ) is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
Hemophilia results from a missing or deficient protein (clotting factor) needed for blood clotting. The two main forms are hemophilia A (factor VIII deficiency) and hemophilia B (factor IX deficiency).
Other Rare Bleeding Disorders are defined by congenital deficiencies of other blood coagulation factors, including Factors II, V, VII, X, and XI.
Alnylam Pharmaceuticals, Inc. (ALNY) reported initial evidence for potential correction of the Hemophilia Phenotype from its ongoing Phase 1 study of ALN-AT3, a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia and rare bleeding disorders.
According to these new data, subcutaneous administration of ALN-AT3 in hemophilia subjects was generally well tolerated, achieved antithrombin knockdown of up to 70%, increased thrombin generation by up to 334%, and markedly improved whole blood clotting.
Thrombin is the principal enzyme of hemostasis, the overall process by which bleeding because of blood vessel damage is halted. It catalyzes the conversion of fibrinogen to fibrin and activates procoagulant factors V, VIII, XI, and XIII.
The ALN-AT3 Phase 1 study continues to enroll hemophilia subjects in additional dose cohorts, including the potential to explore a once-monthly subcutaneous dose regimen following a protocol amendment. ALNY plans to present additional data from the Phase 1 study in mid-2015, and then additional results in late 2015. In addition, ALNY expects to initiate a Phase 2 study of ALN-AT3 in late 2015.
ALNY is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. RNAi is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development.
More about Alnylam Pharmaceuticals, Inc. (ALNY) at www.alnylam.com
**
Xenoport, Inc. (XNPT) reported that sales of HORIZANT(R) (gabapentin enacarbil) Extended-Release Tablets are growing, and the company believes that it has just begun to unlock the potential value of this product for its stockholders.
According to XNPT, the number of nation-wide prescribed tablets for the 13 weeks ending December 19, 2014 was 1,256,082, an increase of 18% compared to the previous 13 weeks and a 95% increase year over year.
The rolling four-week average of prescribed tablets for the week ending December 19, 2014 was 100,742. The current wholesale acquisition cost (WAC) price is $7.69 per tablet
During the third quarter of 2014, XNPT increased its field sales force of NeuroHealth Sales Specialists and believes that prescriptions will continue to experience strong growth in 2015.
XNPT also said that in the fourth quarter of 2014, representatives from the company and the National Institutes for Alcohol Abuse and Alcoholism (NIAAA) conducted a pre-investigational new drug (IND) meeting with the FDA.
Based on the meeting, XNPT believes that the FDA has accepted the NIAAA’s design of the proposed pivotal clinical trial of HORIZANT as a potential treatment for Alcohol Use Disorder.
HORIZANT, discovered and developed by XNPT, was approved in the United States in July 2011 for the treatment of moderate-to-severe primary restless legs syndrome in adults and in June 2012 for the management of postherpetic neuralgia in adults.
XNPT is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders.
More about Xenoport, Inc. (XNPT) at www.XenoPort.com.
**
Crown Equity Holdings Inc. (CRWE) is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included the city of Glendale, California ( www.glendale.crwe-pr.com ) into the CRWE Network.
Glendale is located in southern California. It is the third largest city in Los Angeles County, after LA and Long Beach.
The City of Glendale had an estimated population in 2013 (U.S. Census Bureau) of 196,021, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S., associated with 3456 ZIP Codes, and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance ( www.finance.crwe-pr.com ) is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
